Ayala Pharmaceuticals, Inc. Gains 28.8%

Ayala Pharmaceuticals, Inc. (AYLA:NASDAQ) soared at $10.6, a gain of 28.8%. On Fri, Jul 09, 2021, AYLA:NASDAQ touched a New 2-Week Intraday Low of $8.07. The stock appeared on our News Catalysts scanner on Tue, Jul 06, 2021 at 10:05 AM in the 'MISCELLANEOUS' category. From Fri, Jun 25, 2021, the stock recorded 11.11% Up Days and 30.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About Ayala Pharmaceuticals, Inc. (AYLA:NASDAQ)
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.
Top 10 Gainers:
- Mediaco Holding Inc. (MDIA:NASDAQ), 311.62%
- State Auto Financial Corporation (STFC:NASDAQ), 190.96%
- SGOCO Group, Ltd. (SGOC:NASDAQ), 104.29%
- SCWorx Corp. (WORX:NASDAQ), 59.28%
- TPST (TPST:NASDAQ), 54.37%
- Origin Agritech Limited (SEED:NASDAQ), 40.89%
- CRTD (CRTD:NASDAQ), 33.17%
- Cemtrex, Inc. (CETX:NASDAQ), 31.54%
- Ayala Pharmaceuticals, Inc. (AYLA:NASDAQ), 28.8%
- Celldex Therapeutics, Inc. (CLDX:NASDAQ), 25.49%